Symptoms of Depression and Anxiety in Adults with High-Grade Glioma: A Literature Review and Findings in a Group of Patients before Chemoradiotherapy and One Year Later.
anxiety
depression
high-grade glioma
palliative care
quality of life
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Oct 2022
22 Oct 2022
Historique:
received:
27
07
2022
revised:
03
10
2022
accepted:
13
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
High-grade glioma (HGG) is associated with several external and internal stressors that may induce mood alterations at all stages of the disease. Symptoms of depression and anxiety in persons with glioma have multifactorial etiology and require active follow-up. We reviewed the literature data on the prevalence, mechanisms likely involved in the etiology of mood alterations in persons with HGG and psychosocial interventions found beneficial in treating these symptoms. We also investigated the prevalence and clinical variables that could increase the risk of depression and anxiety symptoms in a group of patients with HGG at two disease time-points: after surgery, before and 1 year after chemoradiotherapy. Literature findings revealed complex mechanisms underlying these symptoms and highlighted the importance of providing early access to palliative care. Our results show a high rate of anxiety and depression symptoms in the first stage of the disease and increased concomitance of these symptoms at the 1-year follow-up. Depression and anxiety symptoms at 1 year after the end of chemoradiotherapy were associated with the presence of symptoms at the first stage of the disease and tumor progression. Antiepileptic drugs and corticosteroid intake did not increase the risk of depressive and anxious symptoms among patients. Active management of mood alterations is an essential part of the care and contributes to patients' well-being and quality of life.
Identifiants
pubmed: 36358611
pii: cancers14215192
doi: 10.3390/cancers14215192
pmc: PMC9659261
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Institut du Cerveau
ID : S.WP13.03.RICARD .
Références
Oncotarget. 2015 Oct 13;6(31):30968-74
pubmed: 26427041
Ann Neurol. 1994 Jul;36(1):48-54
pubmed: 8024261
J Neurooncol. 2012 Jun;108(2):277-83
pubmed: 22392124
Int Rev Psychiatry. 2014 Feb;26(1):31-43
pubmed: 24716499
J Nurs Scholarsh. 2007;39(1):61-7
pubmed: 17393967
Neurosurgery. 2005 Jun;56(6):1234-41; discussion 1241-2
pubmed: 15918939
BMJ. 1988 Oct 8;297(6653):897-9
pubmed: 3140969
J Neurophysiol. 2019 Jan 1;121(1):298-305
pubmed: 30517049
J Neurooncol. 2020 Sep;149(2):347-356
pubmed: 32909116
J Clin Oncol. 2012 Apr 10;30(11):1197-205
pubmed: 22412135
BMJ Open. 2013 Jul 11;3(7):
pubmed: 23847270
Psychooncology. 2010 Jul;19(7):734-41
pubmed: 19777535
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):539-43
pubmed: 18031881
J Neurooncol. 2019 Mar;142(1):183-191
pubmed: 30680509
J Neurooncol. 2016 Jan;126(1):127-135
pubmed: 26419780
Psychooncology. 2018 Feb;27(2):607-612
pubmed: 28801927
Cochrane Database Syst Rev. 2020 Jul 17;7:CD006932
pubmed: 32678464
Curr Opin Oncol. 2010 Nov;22(6):611-20
pubmed: 20706121
Neuropsychopharmacology. 2015 Sep;40(10):2368-78
pubmed: 25833129
World Neurosurg. 2020 Oct;142:e458-e473
pubmed: 32682998
Lancet Neurol. 2007 May;6(5):421-30
pubmed: 17434097
J Neurooncol. 2021 May;153(1):89-98
pubmed: 33822293
Clin Cancer Res. 2013 May 1;19(9):2294-300
pubmed: 23388505
J Neurooncol. 2018 Dec;140(3):739-748
pubmed: 30471051
Nat Rev Neurol. 2017 Jan;13(1):52-64
pubmed: 27982041
Support Care Cancer. 2015 Dec;23(12):3427-35
pubmed: 25761757
BMC Neurol. 2015 Dec 18;15:261
pubmed: 26684198
J Psychosom Res. 1999 May;46(5):437-43
pubmed: 10404478
J Neurosurg Sci. 2012 Sep;56(3):239-45
pubmed: 22854592
Ann Allergy. 1989 May;62(5):375-91
pubmed: 2655506
Acta Oncol. 2002;41(4):346-51
pubmed: 12234025
Lancet. 2012 May 26;379(9830):1984-96
pubmed: 22510398
Neurosurg Rev. 2020 Apr;43(2):497-511
pubmed: 30094499
Lancet Psychiatry. 2017 Apr;4(4):330-338
pubmed: 28109647
Neurosurgery. 2004 Feb;54(2):358-66; discussion 366-7
pubmed: 14744282
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
Acta Neurochir (Wien). 2018 Jun;160(6):1187-1194
pubmed: 29594548
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Arch Neurol. 1993 Aug;50(8):873-80
pubmed: 8352676
Epilepsy Behav. 2017 Nov;76:24-31
pubmed: 28931473
J Neurooncol. 2009 Sep;94(2):153-61
pubmed: 19262993
Cancer Biomark. 2014;14(2-3):185-94
pubmed: 24878820
CNS Oncol. 2015;4(2):71-8
pubmed: 25768331
Neurosci Biobehav Rev. 2019 Jul;102:371-381
pubmed: 31047891
CNS Neurosci Ther. 2018 Nov;24(11):994-1003
pubmed: 29508560
J Neurooncol. 2015 Sep;124(2):185-95
pubmed: 26026860
Annu Rev Med. 2014;65:203-21
pubmed: 24215332
Acta Neurol Scand. 2022 Jul;146(1):82-91
pubmed: 35470866
Transl Psychiatry. 2017 Apr 25;7(4):e1101
pubmed: 28440814
J Neurooncol. 2007 Sep;84(3):297-304
pubmed: 17594056
Neuro Oncol. 2013 May;15(5):635-43
pubmed: 23444258
Nat Rev Immunol. 2016 Jan;16(1):22-34
pubmed: 26711676
Radiat Res. 2020 May;193(5):407-424
pubmed: 32134362
PLoS One. 2016 Jul 08;11(7):e0159059
pubmed: 27391954
Brain Behav Immun. 2020 Jul;87:901-909
pubmed: 32113908
Eur J Cancer. 2017 Feb;72:46-53
pubmed: 28024266
JAMA Psychiatry. 2020 Jun 1;77(6):598-606
pubmed: 31995135
Neural Plast. 2017;2017:6871089
pubmed: 28246558
J Neurosurg. 2008 Feb;108(2):281-6
pubmed: 18240923
Mol Cell Endocrinol. 2021 Jan 15;520:111093
pubmed: 33253761
BMJ Support Palliat Care. 2019 Jun 28;:
pubmed: 31253732
Surg Neurol. 2009 Mar;71(3):299-303, discussion 303
pubmed: 18786716
Psychiatry Clin Neurosci. 2009 Oct;63(5):613-22
pubmed: 19788629
Psychooncology. 2015 May;24(5):540-7
pubmed: 25251838
Psychooncology. 2014 Feb;23(2):121-30
pubmed: 24105788
Neurology. 2006 Jan 24;66(2):239-42
pubmed: 16434662
Cancer Treat Res. 2015;163:171-84
pubmed: 25468232
J Neurooncol. 2014 Sep;119(3):465-72
pubmed: 25026994
Neuro Oncol. 2012 Sep;14 Suppl 4:iv3-7
pubmed: 23095828
Curr Opin Behav Sci. 2019 Aug;28:44-50
pubmed: 31049368
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Expert Rev Clin Pharmacol. 2011 Mar;4(2):233-42
pubmed: 21666852
Neuro Oncol. 2012 Apr;14(4):392-404
pubmed: 22307475
Clin Transl Oncol. 2016 Nov;18(11):1062-1071
pubmed: 26960561
J Neurosci Nurs. 2011 Feb;43(1):17-28
pubmed: 21338041
Front Neurol. 2018 Jul 16;9:577
pubmed: 30061860
Neuropsychiatr Dis Treat. 2015 Apr 22;11:1121-30
pubmed: 25960656
J Neurosurg Sci. 2015 Dec;59(4):383-92
pubmed: 26375636
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
J Natl Cancer Inst. 2012 Jul 3;104(13):990-1004
pubmed: 22767203
Oncotarget. 2017 Aug 03;8(55):94932-94943
pubmed: 29212279
Eur J Cancer Care (Engl). 2018 Mar;27(2):e12806
pubmed: 29314470
Clin Neurol Neurosurg. 2018 Sep;172:8-19
pubmed: 29957299
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Lancet Oncol. 2017 Jun;18(6):e330-e340
pubmed: 28593859
Clin Neurol Neurosurg. 2011 Oct;113(8):649-53
pubmed: 21664761
Ir J Med Sci. 2021 Aug;190(3):1155-1164
pubmed: 33140294